Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Global Testicular Cancer Drugs Market 2014-2018

Global testicular cancer drugs market dominated by Bristol-Myers Squibb Co., Hospira Inc., Teva Pharmaceutical Industries Ltd., and ZIOPHARM Oncology Inc


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-04-11 10:11:02 - Global Testicular Cancer Drugs Market 2014-2018 - a new market research report on companiesandmarkets.com

The Global Testicular Cancer Drugs market is forecast to grow at a CAGR of 4.02 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of testicular cancer. The Global Testicular Cancer Drugs market has also been witnessing the emergence of combination therapies for the treatment of testicular cancer. However, the presence of alternative testicular cancer treatments could pose a challenge to the growth of this market.

Key vendors dominating this space include Bristol-Myers Squibb Co., Hospira Inc., Teva Pharmaceutical Industries Ltd., and ZIOPHARM Oncology Inc.

Other vendors mentioned in the report are Baxter International Inc., Fresenius Kabi Pharmaceuticals Holding Inc., and Mylan Pharmaceutical Inc.

The following companies represent the key players

 

 

in Global Testicular Cancer Drugs Market: Bristol-Myers Squibb Co., Hospira Inc., Teva Pharmaceutical Industries Ltd., and ZIOPHARM Oncology Inc.

The current trend witnessed by the Global Testicular Cancer Drugs market is combination therapy being used for treating testicular cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapy helps in completely removing the tumor or destroying the cancerous cells in the patient´s body. The combination therapy is decided depending on the size of the tumor and the risk of recurrence. Moreover, for treatment of testicular cancer, a combination of two or more drugs is usually given. Some of the combinations are BEP, EP (etoposide and cisplatin), and VIP (vinblastine plus ifosfamide and cisplatin).

One of the key drivers is the increasing prevalence of testicular cancer due to a variety of factors such as congenital abnormalities, family history, abnormal testicular development, and HIV infection. This has increased the demand for testicular cancer drugs as these drugs have greatly improved survival rate for patients with both seminomas and non-seminomas type of testicular cancer.

Further, one of the main challenges in the market is the presence of alternative testicular cancer treatments that do not use drugs, thereby limiting the consumption of drugs.

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com